$40.00USD Testosterone Undecanoate - 250mg (Great cruise option/HRT)

Results 1 to 4 of 4
  1. #1
    P.S.L. Head Rep

    Vision's Avatar

    Join Date
    Aug 2013
    Anabolic Erudite

    Thanks Thanks Given 
    Thanks Thanks Received 
    Thanked in
    3,542 Posts
    Rep Points

    $40.00USD Testosterone Undecanoate - 250mg (Great cruise option/HRT)

    It's almost cruising season, summer is coming to an end...Stock up on one of the most underrated compounds for your cruising needs!

    Do you blast & cruise, are you currently on HRT, are you tired of weekly injections, or are you pinning a lot with your current cycle/blast, getting tired of building scar tissue?

    Well look no further!

    Here we have Testosterone Undecanoate

    "Here at PSL we have all of your HRT/TRT needs covered, with a vast amount of Testosterone ester hormones"


    This shrouded compound is truly a contender in the compound arsenal with great reason, as TU can be utilized in a cruise,HRT or even a cycle stack where multi compounds are implemented.

    Injections scheduling can be decreased with your testosterone in take, at the same time freeing up more injection sites/ for more volume with other compounds, at the same time keeping you test levels up to par with injections as often as every 10-16 days (Half life of Test Undecanoate is 16 days)
    Dosages may range from 250-500 weekly, or 500-1000, and the injections can be spaced out up until 10-14 days (or more)

    TU is used widely in many clinics world wide to treat men with hypogonadism, and HRT therapy..

    The amazing benefits from this compound yields less injections,a much more stable blood environment, less fluctuations, with the convenience of freeing up injection sites for other AAS compounds that may be needed in ones protocol..

    This Test ester is very diverse, serving multi purposes!

    Study below concerning TRT treatment with TU
    __________________________________________________ ___________________
    Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study.


    This paper reports the result of an open-label, non-randomized clinical trial investigating the efficacy and safety of an injectable preparation of testosterone undecanoate (TU) dissolved in castor oil and given over a 3.2-year period. In a previous study we demonstrated that injections of TU every 6 weeks resulted in satisfactory substitution but a tendency toward testosterone accumulation. Here we investigate prolonged TU treatment at extended injection intervals in 7 hypogonadal men. Injections were given at gradually increasing intervals between the fifth and 10th injection, and from then on every 12 weeks. Steady state kinetics were obtained after the 13th injection. Well-being, sexual activity, clinical chemistry, prostate volume, and prostate-specific antigen (PSA) and serum hormone levels were monitored. Patients were clinically well-adjusted throughout the study. Before the next injection, testosterone, dihydrotestosterone, and estradiol levels were mostly within the normal range and showed a tendency to decrease with increasing injection intervals. Body weight, hemoglobin, serum lipids, PSA, and prostate volume did not change significantly during the 3.2 years of treatment. PSA levels were always within the normal limit. Maximal testosterone levels during steady state kinetics were measured after 1 week with 32.0 +/- 11.7 nmol/L (mean +/- SD). Before the last injection, mean testosterone concentrations were 12.6 +/- 3.7 nmol/L. Compared with conventional testosterone enanthate or cypionate treatment requiring injection intervals of 2-3 weeks and resulting in supraphysiological serum testosterone levels, injections of TU at intervals of up to 3 months offer an excellent alternative for substitution therapy of male hypogonadism.

    American Society of Andrology
    Treatment of Male Hypogonadism With Testosterone
    Undecanoate Injected at Extended Intervals of 12 Weeks: A
    Phase II Study

    From the Institute of Reproductive Medicine of the University, D-48129 Munster, Germany

    Testosterone preparations have been in clinical use for
    substitution of male hypogonadism for more than a
    half century. However, only within recent years has the
    choice of different delivery forms increased. The newly
    developed transdermal preparations having short half-
    lives are predominantly tailored for therapy of senescent
    men (Nieschlag, 1998). For substitution of younger hy-
    pogonadal men and for hormonal male contraception,
    long-acting substances are more desirable. Therefore, the
    development and first clinical uses of injectable testoster-
    one buciclate (Behre et al, 1995) and testosterone unde-
    canoate (TU; Partsch et al, 1995; Zhang et al, 1998; Behre
    et al, 1999a) attracted much attention.
    Six-week injections of 1000 mg TU in 4 mL castor oil
    resulted in well-maintained androgen-dependent functions
    without serious side effects (Nieschlag et al, 1999). How-
    ever, after 4 injections, a tendency toward a gradual in-
    crease in testosterone levels was observed, suggesting that
    prolongation of application intervals should be possible.

    In the present paper we report the results of continued
    substitution therapy with TU in 7 hypogonadal men, and
    explore the efficacy and safety of injection intervals of
    up to 12 weeks, for a total period of 3.2 years.

    Materials and Methods

    Seven men with primary or secondary hypogonadism aged 20
    to 57 years, who had already participated in the first trial with
    6-week injections of TU agreed to receive continuing treatment.
    Inclusion and exclusion criteria to enroll patients for TU treat-
    ment have been described previously (Nieschlag et al, 1999).
    Prolongation of the initial study protocol was approved by the
    ethics committee of the university and the State Medical Board,
    Munster. Written informed consent was obtained from subjects.
    Rules for clinical studies as provided by the Declaration of Hel-
    sinki and the standards of good clinical practice were followed.
    Five patients entering the follow-up phase had primary hy-
    pogonadism, and 2 had secondary hypogonadism. The limit of
    serum testosterone for establishing the diagnosis of hypogonad-
    ism in our institute is 12 nmol/L. Diagnosis and the previous
    mode of substitution are given in Table 1. Two men had previ-
    ously participated in the initial study comparing the pharmaco-
    kinetics of TU dissolved in either tea seed (‘‘Chinese prepara-
    tion’’) or castor oil (Behre et al, 1999a)

    May/June 2002
    Table 1.
    Clinical characteristics of patients entering the follow-up phase of substitution therapy with 1000 mg TU
    Patient Diagnosis Age (y)† Treatment (before TU)†

    1 Bilateral orchidectomy due to seminoma 37 TE 250 mg/4 weeks
    2 Bilateral testicular atrophy due to cryptorchidism 19 None
    3 Bilateral orchidectomy due to seminoma age 49 TE 250 mg/3 to 4 weeks
    4 Bilateral orchidectomy due to seminoma age 37 None
    5 Bilateral orchidectomy due to seminoma age 57 TE 250 mg/3 to 4 weeks
    6 Bilateral orchidectomy due to seminoma age 31 TE 250 mg/2 to 4 weeks

    7 Hypogonadotropic hypogonadism (ectopic neurohypophysis age 29 TE 250 mg/4 weeksJournal of Andrology

    * Patients who had already participated in the study on comparative pharmacokinetics with TU in castor oil or tea seed oil.
    † Age and previous treatment modalities refer to the date before the first TU application. TE indicates testosterone enanthate

    Testosterone Preparation

    TU was obtained from Jenapharm GmbH & Co. KG, Jena, Ger-
    many. Each ampule contained 1000 mg TU dissolved in 4 ml
    castor oil. Single injections were administered with the total vol-
    ume at one site intramuscularly into the musculus gluteus med-
    ius, taking care to perform injections slowly to avoid pain.

    Study Design

    The study was a clinical, open label, nonrandomized trial.
    Screening examinations had been completed before the first in-
    jection with TU as described previously (Nieschlag et al, 1999).
    Before the first TU application, all men under current treatment
    completed a washout phase of at least 4 weeks. An overview of
    studies evaluating TU, including the current design, is given in
    Table 2. Before entering the follow-up phase, all patients under-
    went another complete physical and genital investigation and
    assessment of clinical chemistry, hematology, and lipids, as well
    as sonography of testes and prostate. Well-being and sexuality
    were investigated by standardized questionnaires immediately
    before and at half-time between TU injections. Before each ap-
    plication, blood samples for measurements of hormones, sex
    hormone binding globulin (SHBG), albumin, PSA, clinical
    chemistry, lipidology, and hematology were obtained. Prostate
    size was determined sonographically before every second injec-tion.

    After 4 injections had been given at 6-week intervals, the
    intervals were gradually extended between the 5th and 10th in-
    jections. Intervals were extended by 1 to 2 weeks if serum tes-
    tosterone levels were above 12 nmol/L before the next injection,
    and if subjective impairment of well-being was absent. From the
    10th injection onward, TU was applied every 12 weeks. After
    the 13th application, steady state kinetics were obtained as evi-
    denced by weekly determinations of testosterone serum concen-
    trations for 12 weeks. Six weeks after the 18th application, the
    study was finished with a detailed final investigation, including
    a physical and genital examination, sonography of prostate and
    scrotal contents, and all blood values that had been monitoredduring the study.

    Hormone Assays

    Analysis was performed from venous blood samples that were
    centrifuged at 800
    for 10 minutes and then stored at
    until measurements were performed at the end of the study. Care
    was taken so that samples of one subject were measured withinone assay.

    Serum concentrations of follicle-stimulating hormone (FSH),
    luteinizing hormone (LH), estradiol, SHBG, prolactin, and PSA
    were analyzed by highly specific time-resolved immunofluoro-
    metric assays (Autodelfia; Wallac, Freiburg, Germany). The low-
    er detection limits were 0.12 IU/L and 0.25 IU/L for FSH and
    LH, respectively; and 25 pmol/L, 6.3 nmol/L, and 0.5mg/L for
    estradiol, SHBG, and PSA, respectively. The normal range in
    our laboratory is 1–7 IU/L and 2–10 IU/L for FSH and LH,
    respectively, and 11–71 nmol/L for SHBG. The upper limits of
    normal for estradiol and PSA are 250 pmol/L and 4m
    spectively. The intraassay and interassay coefficients of variation
    were 0.5 and 1.9 for FSH, 1.7 and 2.2 for LH, 1.9 and 5.0 for
    estradiol, 1.0 and 7.2 for SHBG, and 3.4 and 4.9 for PSA. Serum
    testosterone was measured by an enzyme-linked immunosorbent
    assay (Biocam Immunosystems; DRG Instruments, Marburg,
    Germany). The lower limit of normal is 12 nmol/L. Dihydrotes-
    tosterone (DHT) was analyzed by radioimmunoassay (DSL
    9600; Diagnostic System Laboratories, Sinsheim, Germany). In-
    traassay and interassay coefficients of variation for testosterone
    and DHT were 3.4 and 5.6, and 4.8 and 9.2, respectively. Free-
    testosterone was calculated using the formula suggested by Ver-
    meulen et al (1999)
    Eckardstein and Nieschlag ·
    Injectable Testosterone Undecanoate

    Clinical Chemistry, Hematology, and Lipids
    Biochemical and hematological parameters were determined at
    the Institute of Laboratory Medicine, University of Mu
    ̈ nster us-
    ing, standard techniques. Quality control was performed accord-
    ing to the standards provided by the German Society of Clinical
    Evaluation of Well-Being and Sexuality
    During treatment patients were asked to complete standardized
    questionnaires to assess mood and sexual performance. Com-
    pleted questionnaires were obtained before injections and at the
    halfway point of the respective injection interval.
    Evaluation of Prostate
    Prostate volume was monitored by transrectal ultrasound using
    a 7.5 MHz probe (The Panther; B&K Medical, Norderstedt, Ger-
    many). Prostate examinations included planimetric determination
    of volume (Behre et al, 2000) and assessment of sonographic
    Statistical analysis was performed using the SPSS statistical
    package for Windows (version 10.0). All variables were checked
    for normal distribution by the Kolmogorov-Smirnov one-sample
    test for goodness-of-fit. Descriptive statistics are given as either
    SD or median, and the 2.5 to 97.5 percentiles. For
    analysis of variance (ANOVA) over time, one-way analysis of
    variance was calculated, which was followed by the Dunnett
    post-hoc test for intergroup comparison if an overall level of
    significance of P

    .05 was reached. When necessary, analysis
    was performed after logarithmic transformation of data.


    General Effects, Well-Being, and Sexual Function
    During TU applications, patients reported stable values
    for all parameters of well-being and sexual function
    (numbers of erections and ejaculations per week and sat-
    isfaction with sex life). At the end of the injection inter-
    val, when questionnaires were compared with those at
    half-time, no statistically significant differences werefound.

    Injections were well tolerated by all men except one,
    who requested extremely slow injections to avoid discom-
    fort. No local side effects or impaired well-being oc-
    curred, except for one occasion when, during prostate so-
    nography, a patient had short-term circulatory problems
    after the injection. One patient complained initially of
    mild acne within 2 weeks following injection. However,
    these problems disappeared during the 12-week intervals.
    In addition, the same patient developed slight gyneco-
    mastia during the first part of the study (6 weekly injec-
    tions), which remained unchanged during the follow-up

    General adverse events related to the treatment were
    not observed. One patient experienced an episode of her-
    pes zoster, which required antiviral therapy after severe
    psychological trauma.
    Body Weight
    During TU applications, body weight increased slightly
    from 83.5
    9.5 kg to 85.7
    9.1 kg without reaching
    the level for statistical significance. Compared with the
    baseline, the maximum mean body weight was observed
    at the end of the study period.
    Testosterone and Free Testosterone
    Testosterone serum levels and calculated free testosterone
    levels obtained before injections are shown in Figure 1.
    During the 6-week injection interval, testosterone levels
    increased initially from 5.2
    3.1 nmol/L to 23.8
    nmol/L after patients had received 4 injections in 6 weeks.
    With extended injection intervals, preapplication testos-
    terone levels decreased and were just at the lower limit
    of normal, with 12.6
    3.7 nmol/L before the last injec-
    tion. A comparable pattern was observed for calculated
    free testosterone levels, which rose to 573
    202 pmol/
    L after the 6-week period, and then returned to the lower
    limit of normal (291
    93 pmol/L) after 8 injections had
    been performed at 12-week intervals.
    Maximum steady state kinetics for levels of testoster-
    one and free testosterone were reached after 1 week. The
    mean maximum concentration for testosterone was 32
    nmol/L, ranging from a minimum of 15.6 to a maximum
    of 44.3 nmol/L. A comparable pattern was observed for
    free testosterone levels, with a mean of 787 pmol/L (Table
    3). Initial kinetics obtained in 14 subjects after the first
    injection of TU and steady state kinetics in the current
    trial are shown in Figure 2.
    Estradiol and DHT
    DHT and estradiol concentrations essentially followed the
    pattern of that for testosterone and free testosterone. Dur-
    ing the short injection intervals, DHT levels occasionally
    exceeded the upper normal limit but returned to the lower
    limit of normal after 5 injections over 12 weeks had been
    applied (Figure 1). Estradiol levels always stayed within
    normal limits.
    LH and FSH
    LH and FSH values decreased significantly during the
    study, from initial values of 18.7
    7.1 IU/L (LH) and 30.5,
    27.3 IU/L (FSH) to 0.4,
    0.8 IU/L (LH) and 1.5,
    2.9 IU/L (FSH) after 24 weeks. Before the last injec-
    tion, LH values of 3.0,
    5.0 IU/L and FSH values of 7.7,
    13.9 IU/L were measured

  2. #2
    Board Rep

    big_rich's Avatar

    Join Date
    Aug 2016

    Thanks Thanks Given 
    Thanks Thanks Received 
    Thanked in
    676 Posts
    Rep Points

    Nice and a good price

  3. #3
    Senior Member

    Oldschool's Avatar

    Join Date
    Jun 2014

    Thanks Thanks Given 
    Thanks Thanks Received 
    Thanked in
    711 Posts
    Rep Points

    This is one helluva good deal!

  4. #4
    Senior Member

    Join Date
    Jul 2016

    Thanks Thanks Given 
    Thanks Thanks Received 
    Thanked in
    49 Posts
    Rep Points

    i need this, it says item not found

Similar Threads

  1. Testosterone Undecanoate - 250mg (Great cruise option/HRT)
    By Vision in forum Purity Source Labs
    Replies: 21
    Last Post: 02-19-2020, 06:52 AM
  2. Testosterone undecanoate 250mg/ml or 500?
    By jacKs4 in forum Purity Source Labs
    Replies: 6
    Last Post: 08-16-2016, 12:42 PM
  3. Testosterone Undecanoate - 250mg/ml
    By XOTG85 in forum UncleZ
    Replies: 5
    Last Post: 03-20-2016, 05:06 AM
  4. Replies: 1
    Last Post: 10-22-2015, 07:58 AM
  5. Testosterone Undecanoate
    By GSRacer in forum Testosterone Replacement Therapy
    Replies: 4
    Last Post: 05-14-2013, 08:58 AM

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
Copyright© 2012-2020 Anabolic Steroid Discussion Forums